Skip to content

Factor V in traumatic coagulopathy

Factor V in traumatic coagulopathy - FITC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53790
Enrollment
12
Registered
2023-02-23
Start date
2023-05-26
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute traumatic coagulopathy Trauma-induced coagulopathy

Interventions

None listed

Sponsors

Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Male - Age 18-35

Exclusion criteria

Exclusion criteria: -Participation in a scientific intervention study in the last 3 months -No informed consent -History of coagulation disorders -Active use of prescription medication -Use of anticoagulant medication, including aspirin -History of liver disease -History of chronic transmittable disease -History of alcohol, smoking or drug abuse

Design outcomes

Primary

MeasureTime frame
Objective 1 In vitro: what are the factors related to factor V depletion in trauma-induced coagulopathy Objective 2: In vitro: whether factor V supplementation either alone or in combination with other factors (PCC and/or fibrinogen) is associated with improvement in clot build-up determined by ROTEM

Secondary

MeasureTime frame
In vitro coagulation will be assessed through multiple methods, for example: - ROTEM - Thrombin generation assay - Platelet function (aggregometry, flow cytometry, adhesion under flow) - Plasma coagulation proteins - Blood group, Hb/HCT, platelet count

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)